Skip to content

A verification study of the suppressive effect of the test food consumption on the elevation of postprandial blood glucose

A verification study of the suppressive effect of the test food consumption on the elevation of postprandial blood glucose: a randomized, placebo-controlled, double-blind, crossover comparison trial - A verification study of the suppressive effect of the test food consumption on the elevation of postprandial blood glucose

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000048012
Enrollment
34
Registered
2022-06-09
Start date
2022-06-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese subjects

Interventions

Period I: Capsule containing Siraitia grosvenorii extract (mogrol) Period II: Placebo capsule Carbohydrate load: &quot
retort cooked rice) After collecting blood samples prior to the ingestion of test foods, take one active or placebo capsules with water. Then, take the carbohydrate load within 10 minutes. Swallow

Sponsors

ORTHOMEDICO Inc.
Lead Sponsor
Medical Corporation Seishinkai, Takara Clinic Nerima Medical Association, Minami-machi Clinic
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Japanese 2. Men or women 3. Subjects aged 20 or more 4. Healthy subjects 5. Subjects whose blood glucose levels are relatively high 6. Subjects whose IAUC of postprandial blood glucose are relatively large at screening (before consumption) 7. Subjects who are judged as eligible to participate in the study by the physician

Exclusion criteria

Exclusion criteria: 1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Subjects who currently undergoing treatment for any of the following chronic disease: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Subjects who take "Foods for Specified Health Uses," "Foods with Functional Claims," or other functional food/beverage in daily use 5. Subjects who currently taking medications (including herbal medicines) and supplements 6. Subjects who are allergic to medicines and/or the test food related products 7. Subjects who are pregnant, lactation, or planning to become pregnant 8. Subjects who suffer from COVID-19 9. Subjects who have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial 10. Subjects who are judged as ineligible to participate in the study by the physician

Design outcomes

Primary

MeasureTime frame
1. The incremental area under the curve (IAUC) of the postprandial blood glucose

Secondary

MeasureTime frame
1. The maximum blood concentration (Cmax) of the postprandial glucose 2. IAUC of insulin in the postprandial blood 3. The blood glucose and insulin before consumption of the test food and 30, 60, 90, and 120 minutes after carbohydrate load

Countries

Japan

Contacts

Public ContactNaoko Suzuki

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026